2015 - Pharma Jobs- PJ

Pharma Jobs- PJ

A DESTINATION FOR PHARMA JOBS SEEKERS.___________PJ MOTTO:- SHARE MORE, YOU WILL GET MORE.

Thursday, 31 December 2015

Walk-In interview for QC, QC Micro, QA (IPQA, Validation & QMS) @ Amneal pharma.

Job Location : Ahmedabad
Date : 3rdJan 2016 (Sunday)
Timings: 9:30 am to 1:30 pm

Walk-In-Interview Venue   :
Amneal Pharmaceuticals Pvt Ltd, 5th floor, 508-514, Venus Atlantis Corporate park, Prahladnagar Road,
Ahmedabad-380051
Contact                                  :


If you have the talent and the zeal here’s an opportunity for you to join our Injectable manufacturing plant at Ahmedabad as:

(1) Officer/Sr.officer/Executive/Sr.Executive - Quality Control - (50 Vacancies)

(2) Officer/Sr.Officer/Sr. Executive/Executive
-- QC Micro (20 Vacancies)

(3) Officer/Sr. Officer/Sr. Executive/Executive -- Quality Assurance (IPQA, QMS & VALIDATION) -- 30 Vacancies

For above position following education  required  like
B.Sc. / B.Pharm / M.Sc. with 1 to 10 years of experience

Candidates must have exposure to regulatory requirements of documentation and cGMP/GLP .

Interested candidates may “Walk-in” for an interview along-with their updated CVs and relevant documents.

Those who are unable to attend walkin interview they can also share there CV on chandanid@amnealindia.com or manojm@amnealindia.com
(Fresher can only share there CV on above mail I'd only)
Regards,
Team HR.

Greetings from Dr Reddys Laboratories Ltd
For our API Manufacturing Units at Hyderabad, Miryalaguda and Vizag we have a scheduled interview on 03-Jan-2016 (Sunday) starts at 09.00am to 11 am.


Dr.Reddy's Laboratories Ltd.
CPS (Custom Pharmaceutical Services)
JP Nagar Cross road, Near Miyapur X Roads,
Hyderabad, Telangana.
Tel: 040-4465 7100.
If your profile fit into the below position details, you can walk in along with your updated CV and last month salary slip.
Post graduates in Science with minimum 3 to 15 years' experience in Quality Assurance with leading Pharma companies in API. Establish and control system for release/ rejection of APIs, Intermediates, Raw materials and Packaging Materials. Establish and control a system for review of completed batch records and laboratory records before release of API batches for distribution. Investigate market complaints / return goods/recalls and recommend corrective measures in consultation with plant management to make sure that are resolved. Candidates should have strong exposure to reviewing and approving validation qualification, technology transfer protocols and reports and ensure compliance to validation master plan related to API manufacturing using state of the art technology is a must.
The candidates should be open to work at any of the API Plants in Andhra Pradesh & Telangana.
Note : Freshers please ignore this mail
Kindly ignore if this is not applicable for you
Regards
Talent Acquisition Team-HR
Dr Reddy's LaboratoriesLtd

Hyderabad.

Monday, 28 December 2015

    Walk-in for Production on 29th December 2015 at Ankleshwar 

    Here is a chance to join Zydus at our API Manufacturing located at Ankleshwar as.


    PRODUCTION : Officers / Executive  : Diploma /B.E / B.TECH (chemical) M.Sc./ B.Sc. (Chemistry) with 2 to 7 years of experience and relevant exposure in API / Bulk Drug Manufacturing. Should also have knowledge of GMP documentation. Must be familiar with cGMP requirements. 


    Interested candidate may Walk-In for Interview along with their CVs and relevant documents at

    Date: 29th December  2015 (Tuesday)

    Time: 09:30 AM to 05:00 PM

    Venue: Cadila Healthcare Ltd. 
    Plot No.291, 
    GIDC Industrial Estate,
    Ankleshwar-393 002. 
    Dist-Bharuch. Gujarat.
     


    Contact No of HR representative: 02646-660408 / 660507

    Candidates having experience of working in regulatory approved plants and possesses sound knowledge of documentation, cGMP and SAP will be preferred.

    Those who are unable to attend the Personal Interview may send their resume through e-mail at ank.hr@zydusmail.com

    Please mention the position applying for on the top of envelope or subject in case of e-mail.

    Preference will be given to candidates having API - Pharmaceutical Industries experience.


    Walk-in for Quality Control and Quality Assurance  on 06th January 2016 at Ankleshwar 

    Here is a chance to join Zydus at our API Manufacturing located at Ankleshwar as.


    QUALITY CONTROL : Officers / Executive  : M.Sc /B.Sc (Chemistry) with 2-8 years of hands on experience and relevant exposure in handling instruments like HPLC, GC, UV , wet lab and chemical analysis of Raw Material . Must be familiar with cGMP requirements. Shop floor Operation in API / Bulk Drug Manufacturing.

    QUALITY ASSURANCE : Sr.Executive / Executive : M.Sc./ B.Sc Chemistry with 2-8 year , must be familiar with cGMP requirements, Data Integrity, Document Cell, Batch release process, Trending APR shop floor Operation in API / Bulk Drug
    Manufacturing.

    a) Data Integrity - Responsible to review of HPLC and GC , QC Sop Compliances, Investigation activities , OOS and OOT and quality control instruments.

    b) Document Cell - Review of documents before DMF submissions, distribution / Issuance of BMRs, Master Formulae, SOPs and Formats to the respective departments and controlling all master documents.

    c) Batch Release - Knowledge of ICH guidelines and should review of BMR;s and Validation documents and to give usage decision and dispatch of all APIs and salable intermediates in LIMS and SAP.

    d) Technology transfer documents - Review and issuance TTD to plant , review of master batch record also review of specification and STP of API, Intermediate, RM, In-process.

    e) Trending and APR - Knowledge of Market complaint, Deviation, Incident, Change control for trending of Systems, Review of Master SOPs, BMRs, PCRs, Trial batch reports, validation Protocols and reports and Annual Review reports.


    Interested candidate may Walk-In for Interview along with their CVs and relevant documents at

    Date: 11th January 2016 (Monday) 

    Time: 09:30 AM to 05:00 PM

    Venue: Cadila Healthcare Ltd. 
                  Plot No.291, 
                  GIDC Industrial Estate,
                  Ankleshwar-393 002. 
                  Dist-Bharuch. Gujarat.
     


    Contact No of HR representative: 02646-660408 / 660507

    Candidates having experience of working in regulatory approved plants and possesses sound knowledge of documentation, cGMP and SAP will be preferred.

    Those who are unable to attend the Personal Interview may send their resume through e-mail at ank.hr@zydusmail.com

    Please mention the position applying for on the top of envelope or subject in case of e-mail.

    Preference will be given to candidates having API - Pharmaceutical Industries experience.


Executive / Sr.executive - Quality Assurance at API Ankleshwar

Cadila Healthcare Limited - Akleshwar

EXPEREINCE ;- 2 - 7 yrs



    Executive / Sr.Executive-  Quality Assurance  at API Ankleshwar 

    Here is a chance to join Zydus at our API Manufacturing Multi Product Plant located at Ankleshwar as.

    Key Responsibilities are mentioned as below:

    QUALITY ASSURANCE : Sr.Executive / Executive   :   M.Sc./ B.Sc Chemistry with 2-8 year , must be familiar with cGMP requirements, Data Integrity, Document Cell, Batch release process, Trending APR shop floor Operation in API / Bulk Drug
     Manufacturing.

    a) Data Integrity - Responsible to review of HPLC and GC , QC Sop Compliances, Investigation activities , OOS and OOT and quality control instruments.

    b) Document Cell - Review of documents before DMF submissions, distribution / Issuance of BMRs, Master Formulae, SOPs and Formats to the respective departments and controlling all master documents.

    c) Batch Release - Knowledge of ICH guidelines and should review of BMR;s and Validation documents and to give usage decision and dispatch of all APIs and salable intermediates in LIMS and SAP.

    d) Technology transfer documents - Review and issuance TTD to plant , review of master batch record also review of specification and STP of API, Intermediate, RM, In-process.

    e) Trending and APR - Knowledge of Market complaint, Deviation, Incident, Change control for trending of Systems, Review of Master SOPs, BMRs, PCRs, Trial batch reports, validation Protocols and reports and Annual Review reports.

    Interested candidate may send there CV updated on ank.hr@zydusmail.com  


    Contact No of HR representative: 02646-660408 / 660507

    Candidates having experience of working in regulatory approved plants and possesses sound knowledge of documentation, cGMP and SAP will be preferred.


    Please mention the position applying for on the top of envelope or subject in case of e-mail.

    Preference will be given to candidates having API - Pharmaceutical Industries experience.

DGM Project - Formulations


experience:- 6 - 11 Years

location:-Ahmedabad
Openings: 1
Job Description
Skills & Responsibilities:
Driving complete execution of projects, from the stage of conception to delivery including cost control, scope management, purchase, order receipt and final product dispatch
Managing end to end Project Lifecycle entailing planning, scheduling, tracking and monitoring projects and working in coordination with teams like PR&D, AR&D, SCM, PE, QA, QC, Regulatory, Logistics, Vendors, 3rd Parties & Production
Keeping close track of progress of projects using appropriate tools and communicating the same to all stakeholders; devising contingency plans and identifying & mitigation risks
Undertaking close review of all projects with key stakeholders, obtaining project sign off, reconciling schedules & cost variance and archiving the lessons learned
Conceptualizing & implementing business plans for development of molecules, by working in close coordination with Business Development Managers and Marketing Managers
Analyzing clients needs and serving as a single point contact for all customers; providing end-to-end service to customers in the domains of development, manufacturing & supply of APIs & Intermediates to global Pharma
companies; Visiting clients for face to face meetings and coordinating client visits to R&D and manufacturing sites
Providing extensive assistance to the Business Development Team for preparing proposals and quotes

Contact Details
Recruiter Name:Mr.Sanjay Zankat
Contact Company:Cadila Pharmaceuticals Limited
Telephone:91-79-225001-15
Address :Cadila Corporate Campus Sarkhej - Dholka Road, ,Bhat, ,AHMEDABAD,Gujarat,India

Open Interview for "Quality Control-OSD" at Amneal, Ahmedabad for Analyst & Reviwers on 27th Dec'15-Sunday.

Exp: 2-8 yrs.
Pls send CV at aartig@amnealindia.com

We will send you "Interview Call Letter" if profile will get shortlisted.

Regards,
Aarti Gadhavi
Amneal Pharma

Thursday, 24 December 2015

Require the following:- A) 4 candidates for NDDS Analysis. Education: MPharm Experience: 3-5 yrs. (Transdermal / Injectable) B) 8 candidates for Finished Product Analysis. Education: MPharm / MSc (if experienced). Experience: 4-5 yrs. C) 2 candidates for Stability Chambers. Education: BPharm or BSc. Experience: 4-6 yrs. D) 4 candidates for Document Cell for ADL. Education: BPharm/MPharm. Experience: 3-5 yrs. E) 4 candidates for Quality Control API EXPEDIENTS. Education: BPharm or BSc. Experience: 2-5 yrs. Location: Emcure Pharmaceuticals Limited, Adalaj, Gandhinagar.
REFERENCE :- RATHORE DIPAK mail: joseph.ambrose@emcure.co.in

Dear Candidate,

We have scheduled Walk-In for Torrent Pharmaceuticals Ltd., Indrad Plant on 27th December, 2015 (Sunday)

INTERVIEW DATE & TIME:
Date: 27th December, 2015 (Sunday)
Time: 10:00 am - 04:00 pm

Job Location: Ahmedabad (Indrad Plant)

INTERVIEW VENUE:

1. RANGPO TOURIST LODGE (SIKKIM) 
EAST SIKKIM,
RANGPO

2.FORTUNE PARK GALAXY (VAPI)
Near Gunjan Cross Roads,
N. H. No. 8, G.I.D.C.,
VAPI, GUJARAT

3.HOTEL NAMI RESIDENCY (AHMEDABAD) 
OPP. V. S. HOSPITAL,
ELLISBRIDGE, 
AHMEDABAD, GUJARAT

Department: QUALITY CONTROL 
Section: Formulation, Stability, Method Validation & API
Qualification: B.Sc. / M.Sc / B.Pharm / M.Pharm
Experience: 1 - 8 years in Reputed Pharmaceutical Industry
Designation: Executive / Technical Assistant

Brief Job requirements: 
-Analysis of Finished product, Stability samples and Raw Material as per Method of Analysis
-Analytical Method Development, Verification and Validation
-Responsible for preparation of Specification and STP, Data interpretation and Troubleshooting
-Preparation of Method Verification Protocols and Raw-data sheet 
-Sound knowledge of HPLC/ GC / Dissolution & Chemical Analysis

Preference will be given to those who are having experience of working in API/ Formulation regulatory approved plants.

Candidates may Walk-In for an interview along with their updated Resume & Passport size photograph.

Documents required: 
Photocopy of all Marksheets, School Leaving Certificate, PAN card, Salary Slips (last six months), Increment Letter

Regards,
Mayur Desai
Human Resources
Torrent Pharmaceuticals Ltd.
Office line: 9879603921/ 22/ 23/ 24/ 25
Mobile No. 75674 66633, 990 990 5477

E-mail: aswinmpatel@torrentpharma.com,mayurdesai@torrentpharma.com

Tuesday, 22 December 2015

Reference
Rathore dipak
Pharma Jobs-PJ
Admin

Vacancy for IRA Executive.

Exp: 5 to 6 yrs

Any male & female

Interview date : 24 Dec 2015(Thursday)

Contact person : Yash Bharucha
9099724666
yash.bharucha@clarisotsuka.com

Walk-In interview for QUALITY CONTROL @ Zydus cadila.

Job Location : Ahmedabad
Date : 2ndJan 2016 (Saturday)
Timings: 9:30 am to 4:30 pm

Walk-In-Interview Venue   :
Cadila Healthcare Ltd., Sarkhej-Bavla NH-8A, Moraiya, Taluka-Sanand, Ahmedabad-382210
Contact                                  : 02717 666 436

Zydus Cadila is one of India’s leading healthcare companies and a global healthcare provider with strengths all along the pharmaceutical value chain. The group’s state-of-the-art manufacturing infrastructure is spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim. The group’s formulation manufacturing hub at Moraiya, Ahmedabad has received approvals from several regulatory authorities.

In keeping with its ethos of ‘We build people to build our business’ the group has created a benchmark in HR practices and uses scientific and objective methodologies like psychometric tools, in-house Assessment Centers etc., as a part of its recruitment process.

If you have the talent and the zeal here’s an opportunity for you to join our manufacturing plant at Ahmedabad as:

Chemist / Officer - Quality Control

B.Sc. / B.Pharm / M.Sc. with 2 to 8 years of hands-on experience of HPLC, GC, dissolution apparatus and UV-visible spectrometer. Should also have knowledge of weight analysis and stability studies for parenteral preparations and solid dosage forms


For above positions, candidates must have exposure to regulatory requirements of documentation and cGMP/GLP . Those with experience in SAP environment shall be preferred.

Interested candidates may “Walk-in” for an interview along-with their updated CVs and relevant documents.

Interested Candidates may also email their resume to hr.mfg@zydusmail.com or send it by courier to the Human Resource Department, Cadila Healthcare Ltd., Sarkhej-Bavla NH-8A, Moraiya, Taluka-Sanand, Ahmedabad-382210 within 7 days..

Regards,
Team HR.

MENTION MY REFERENCE 

from samanvay pharmacy college botad

we need a fresher professor in 

*medicinal chemistry,
*microbiology and 
*cognosy



those who are intrested tell them to send resume on presidentsamanvay@gmail.com

Granules India facility gets 3 observations during USFDA audit


New Delhi: Drug firm Granules India has received three observations from the USFDA for its Jeedimetla, Hyderabad facility during a recent inspection.
US Food and Drug Administration (USFDA) completed the inspection of company's two facilities, one located at Vizag in Andhra Pradesh and another at Jeedimetla in Telangana, Granules India said in a regulatory filing.
"There are no observations for Vizag facility and three observations for Jeedimetla facility. The company will respond to the observations in 15 business days", it added.
The Hyderabad-based firm serves customers in over 60 countries and has manufacturing footprint in India and China.
It has three facilities in Hyderabad and one in Jingmen, China. A fifth factory is under construction in Vizag through its JV company Granules OmniChem.
Granules India shares today ended at Rs 157.65
apiece on the BSE, up 2.17 per cent from the previous close. MSS ANU

Sun Pharma falls 7.4% on fresh FDA alert


Sun Pharma fell 7.4 percent after the company got a warning letter from the US Food and Drug Administration (FDA) for its facility located at Halol, Gujarat.

The fresh warning letter to the company comes after the facility was first inspected by the US drug regulator in September 2014. In a release issued to BSE, Sun Pharma said: "Post the September 2014 inspection, the USFDA has withheld future product approvals from the Halol facility.

This situation may continue until all issues are resolved. Sun Pharma expects to request a re-inspection by USFDA upon completion of its remediation commitments." In intra-day trade, the stock touched a low of Rs 732, before recovering to end at Rs 755.


Glenmark gets USFDA final nod for anti-bacterial drug Zyvox

NEW DELHI: Glenmark Pharmaceuticals has received the final nod from the US health regulator for a generic version of anti-bacterial drug Zyvox.

"Glenmark Pharmaceuticals Inc, USA, has been granted final approval by the US Food & Drug Administration (USFDA) for the Linezolid tablets, 600 mg," Glenmark Pharmaceuticals said in a statement.

The product is the therapeutic equivalent of Zyvox tablets, 600 mg of Pharmacia and Upjohn Company, a subsidiary of Pfizer, it added.

According to IMS Health sales data for the 12 months to October 2015, Zyvox tablets, 600 mg, achieved annual sales of around USD 447.6 million, Glenmark said.

Zyvox is an anti-bacterial drug marked for adults and children for treatment of infections such as pneumonia, complicated skin and skin structure infections, including diabetic foot infections.

With today's approval, the company's current portfolio consists of 104 products authorised for distribution in the US marketplace and 62 abbreviated new drug applications (ANDA) pending approval with USFDA.

Glenmark Pharmaceuticals was trading at Rs 938.60 on BSE, up 1.21 per cent, at 1112 hours

Aurobindo Pharma gets USFDA nod for its conjunctivitis drug

the strength of 0.1 per cent," Aurobindo Pharma said in a.


New Delhi, Dec 22 : Drug firm Aurobindo Pharma has received approval from the US health regulator for generic Olopatadine Hydrochloride ophthalmic solution used for treatment of seasonal allergic conjunctivitis and is ready to launch the product in the American market.
"The company has received final approval from the United States Food & Drug Administration (USFDA) to manufacture and market Olopatadine Hydrochloride Ophthalmic Solution USP in the strength of 0.1 per cent," Aurobindo Pharma said in a regulatory filing today.
The product is generic version of Alcon Laboratories Inc's Patanol ophthalmic solution/drops in the same strength, it added.
"The approved product has an estimated market size of USD 235 million for the 12 months ending October 2015, according to IMS," Aurobindo Pharma said.
The company currently has a total of 225 abbreviated new drug application (ANDA) approvals (197 final approvals including 10 from Aurolife Pharma LLC and 28 tentative approvals) from USFDA, it added.
The stock was today trading at Rs 845.50 in the afternoon trade on BSE, up 1.05 per cent from its previous close. AKT ARD

Cipla launches generic hepatitis C drug 'Hepcvir-L' in India

Cipla has launched generic tablets used for treating of hepatitis C under the brand name 'Hepcvir-L' costing Rs 25,000 for a bottle of 28 tablets in India.
New Delhi: Drug major Cipla has launched generic tablets used for treating of hepatitis C under the brand name 'Hepcvir-L' costing Rs 25,000 for a bottle of 28 tablets in India.

Cipla MD and Global Chief Executive Officer Subhanu Saxena said, "The launch of Ledipasvir-Sofosbuvir is a further step to facilitate the optimal treatment for patients suffering from genotype 1 hepatitis C virus."

The company's product is a generic version of the S-based drug maker Gilead Sciences Inc's Harvoni tablets.

"Globally, the burden of Hepatitis C is around 185 million. About 12-18 million Indians are infected with this disease," it added.

Hepcvir-L is the first once-a-day, fixed dose oral combination therapy that has been approved for chronic hepatitis C genotype 1 patients, Cipla said.

The company's current portfolio includes over 1,500 products across therapeutic categories.

Cipla was trading at Rs 646.15, up 0.62 per cent, on the BSE.

Monday, 21 December 2015

Exclusive: India’s Sun Pharma in ‘early talks’ to buy rival Intas in blockbuster $2b deal

Photo: Hemant Mishra/Mint
Photo: Hemant Mishra/Mint
Bhawna Gupta
bhawna@dealstreetasia.com December 21, 2015: 
After bringing Ranbaxy into its fold last year, India’s top drug-maker by market value Sun Pharmaceutical Industries Ltd is now setting its sights to acquire local rival Intas Pharmaceuticals Ltd, and is in ‘early talks’ in what could be a Rs 15,000 crore ($2.3 billion) deal, multiple sources familiar with the development told DEALSTREETASIA.

Intas Pharma is among India’s top 15 pharma companies, and counts Singapore’s sovereign wealth fund Temasek as of its investors. It manufactures, markets and sells biosimilars, which are generic versions of biologic drugs.

This cash-cum-stock deal will see Sun Pharma cough up Rs 7,500 crore in cash and issue shares for the remaining amount, said one of the executives who is directly aware of the development and requested anonymity, and is among those quoted above.

If the deal materialises, it will mark Sun Pharma’s second largest acquisition in India after it completed the merger of Ranbaxy in March 2015 in a stock deal valued at $4 billion. That deal had got completed after almost a year of announcing it.

Sun Pharma has hired Kotak Mahindra while Intas Pharma has appointed a leading Mumbai-based advisory firm to lead the mandate for the proposed deal, said another of the executives quoted above.

Founded in 1976, Ahmedabad-based Intas Pharma manufactures tablets, capsules, parenterals and cytotoxic formulations for central nervous system (CNS), cardiovascular, diabetology, gastroenterology, urology, pain management, animal health care, oncology and biotechnology.

In 1996, the company set up a plant in Ahmedabad. Five years later, it started exporting to Europe.

Currently, the company is going to launch Amgen Inc’s white blood cell boosting Neulasta drug in the US which will help it to become first Indian firm to sell biosimilars in the US, according to a Reuters report.

Responding to an email sent by DEALSTREETASIA seeking confirmation and more information on the development, a Sun Pharma spokesperson declined to comment.

In a separate email response, Jayesh Shah, CFO, Intas Pharma, said, “this is baseless and we completely deny the report.”

Kotak Mahindra Capital’s spokesperson also denied to comment on the deal.

In 2014, Temasek bought little over 10 per cent stake in Intas Pharma from PE firm ChrysCapital which invested in the company in 2005 and 2012.

The pharma company, which got SEBI’s approval in September this year to hit the public market, wanted to provide a partial-exit to ChrysCapital through the market route but it later skipped the plan. It also filed papers in 2011 and 2013 for an IPO but could not go ahead with its market debut owing to weak market conditions.

Sun Pharma has been in the news recently for received a warning letter from the U.S. Food and Drug Administration (USFDA) over violation of manufacturing norms in its facility at Halol in Gujarat.

Sun Pharma has been active with acquisitions and divestments this year. Last week, it sold its manufacturing plants in Ohio, US to Nostrum Laboratories. In November 2015, Sun Pharma bought US-based eyecare firm InSite Vision, which became its wholly-owned subsidiary.

2015 has been marked by a surge of M&As, led by healthcare and pharma space. After Sun Pharma-Ranbaxy deal in July, India’s third-largest drugmaker by sales Lupin acquired Russia-based ZAO Biocom for an undisclosed amount. This came a couple of months after it bought Brazil’s Medquímica Indústria Farmacêutica.

In September, another drug maker Cipla acquired US-based InvaGen Pharmaceuticals Inc and Exelan Pharmaceuticals Inc. In May, Strides Arcolab, a Bangalore-based pharmaceutical company, acquired the Australia business of Aspen for $287 million.

India, which is among the global leaders in producing generics, is expected to be one of the top 10 pharma markets by sales and reach a value of around $50 billion by 2020, as per a report by PricewaterhouseCoopers.

Shares of Sun Pharma closed at Rs 754.45 each, down 4.55 percent on BSE in a strong Mumbai market on Monday.

For the quarter ended Sept 30, 2015, Sun Pharma reported a consolidated net profit of Rs 1,106.66 crore, had a loss of 46 percent as compared with last year’s Rs 2,050.22 crore for the same quarter. Its net sales decreased to Rs 6,803.31 crore for the same quarter from Rs 7,979.31 crore in 2014.

Dear Candidate,

Greetings from Safix Hutech!!!

We have the following vacancy and the details are given below

About the Company: Its a pharma MNC company.

Name of the Position/Designation: Exe/Sr.exe (Tech transfer)

Years of Experience: 2- 6 yrs

Location: Bangalore

Salary:

Job Description:

1. To review all documents related to demonstration, process optimization, Exhibit and Validation batches.

2. Review of developmental data such as Process, Trial details, APIs and Excipients

3. To resolve all issues relating to technology transfer with the Formulation Team.

4. To provide knowledge transfer to Plant for demonstration of batch manufacturing

5. Evaluation of specifications, tests conducted and other processes

6. To conduct optimization studies and worst case scenarios

7. To provide troubleshooting support to plants

8. To suggest and recommend cost optimization methods

9. To address all process related queries to Regulatory Affairs/Regulatory Bodies

10. Coordination with stakeholders such as FRD, ARD, RA, DQA, Site Tech Transfer, Site QA & Project Management

If the above requirement does not suit your profile kindly ignore the mail.

If your profile matches the above requirement and if you're interested in the above opening kindly email your resume at the earliest as word document attachment to (YOUR EMAIL ID) without changing the subject line.

Current CTC:
Expected CTC:
Notice Period:
Total Experience:

If any of your friends / colleagues profile matches the above requirement, kindly suggest them to apply. For any further clarification feel free to mail.

-
Thanks & Regards,
Kavitha R Johnson
IT Recruiter

Safix Hutech Pvt. Ltd.
Bangalore
Phone Number : 9108459656, 080-47737009
Email Id: kavitha@safixhutech.com

Tablet:Manufacturing methods/Granulation

Introduction

Granulation may be defined as a size enlargement process which converts small particles into physically stronger & larger agglomerates.
Granulation method can be broadly classified into two types: Wet granulation and Dry granulation
Ideal characteristics of granules
The ideal characteristics of granules include spherical shape, smaller particle size distribution with sufficient fines to fill void spaces between granules, adequate moisture (between 1-2%), good flow, good compressibility and sufficient hardness.

The effectiveness of granulation depends on the following properties
i) Particle size of the drug and excipients
ii) Type of binder (strong or weak)
iii) Volume of binder (less or more)
iv) Wet massing time ( less or more)
v) Amount of shear applied
vi) Drying rate ( Hydrate formation and polymorphism)

Wet granulation


Introduction
The most widely used process of agglomeration in pharmaceutical industry is wet granulation. Wet granulation process simply involves wet massing of the powder blend with a granulating liquid, wet sizing and drying.

Important steps involved in the wet granulation
i) Mixing of the drug(s) and excipients
ii) Preparation of binder solution
iii) Mixing of binder solution with powder mixture to form wet mass.
iv) Coarse screening of wet mass using a suitable sieve (6-12  screens).
v) Drying of moist granules.
vi) Screening of dry granules through a suitable sieve (14-20  screen).
vii) Mixing of screened granules with disintegrant, glidant, and lubricant.


Limitation of wet granulation
i)The greatest disadvantage of wet granulation is its cost. It is an expensive process because of labor, time, equipment, energy and space requirements.
ii)Loss of material during various stages of processing
iii)Stability may be major concern for moisture sensitive or thermo labile drugs
iv)Multiple processing steps add complexity and make validation and control difficult
v)An inherent limitation of wet granulation is that any incompatibility between formulation components is aggravated.

Special wet granulation techniques
i) High shear mixture granulation
ii) Fluid bed granulation
iii) Extrusion-spheronization
iv) Spray drying


1.High shear mixture granulation
High shear mixture has been widely used in Pharmaceutical industries for blending and granulation. Blending and wet massing is accompanied by high mechanical agitation by an impeller and a chopper. Mixing, densification and agglomeration are achieved through shear and compaction force exerted by the impeller.
Advantages:
i) Short processing time
ii) Less amount of liquid binders required compared with fluid bed.
iii) Highly cohesive material can be granulated.


2.Fluid bed granulation
Fluidization is the operation by which fine solids are transformed into a fluid like state through contact with a gas. At certain gas velocity the fluid will support the particles giving them free mobility without entrapment.
Fluid bed granulation is a process by which granules are produced in a single equipment by spraying a binder solution onto a fluidized powder bed. The material processed by fluid bed granulation are finer, free flowing and homogeneous.

3.Extrusion and Spheronization
It is a multiple step process capable of making uniform sized spherical particles. It is primarily used as a method to produce multi-particulates for controlled release application.
Advantages:
i) Ability to incorporate higher levels of active components without producing excessively larger particles.
ii) Applicable to both immediate and controlled release dosage form.


4.Spray drying granulation
It is a unique granulation technique that directly converts liquids into dry powder in a single step. This method removes moisture instantly and converts pumpable liquids into a dry powder.
Advantages:
i) Rapid process
ii) Ability to be operated continuously
iii) Suitable for heat sensitive product


Lists of equipments for wet granulation

High Shear granulation:
i)Little ford Lodgie granulator
ii)Little ford MGT granulator
iii)Diosna granulator
iv)Gral mixer

Granulator with drying facility:
i) Fluidized bed granulator
ii) Day nauta mixer processor
iii) Double cone or twin shell processor
iv) Topo granulator
Special granulator:
i) Roto granulator
ii) Marumerizer

Current topics related to wet granulation
I.Hydrate formation
For example, theophylline anhydrous during high shear wet granulation transfers to theophylline monohydrate. The midpoint conversion occurs in three minutes after the binder solution is added.
For online monitoring of the transformation from one form to another, Raman spectroscopy is most widely used.
II.Polymorphic transformation
The drying phase of wet granulation plays a vital role for conversion of one form to another.
For example, glycine which exist in three polymorphs that is α β γ . γ is the most stable form and αis the metastable form. The stable Glycine polymorph (γ) converts to metastable form (α) when wet granulated with microcrystalline cellulose.


Dry granulation


Introduction
In dry granulation process the powder mixture is compressed without the use of heat and solvent. It is the least desirable of all methods of granulation. The two basic procedures are to form a compact of material by compression and then to mill the compact to obtain a granules. Two methods are used for dry granulation. The more widely used method is slugging, where the powder is precompressed and the resulting tablet or slug are milled to yield the granules. The other method is to precompress the powder with pressure rolls using a machine such as Chilosonator.


Advantages
The main advantages of dry granulation or slugging are that it uses less equipments and space. It eliminates the need for binder solution, heavy mixing equipment and the costly and time consuming drying step required for wet granulation. Slugging can be used for advantages in the following situations:
i) For moisture sensitive material
ii) For heat sensitive material
iii) For improved disintegration since powder particles are not bonded together by a binder

Disadvantages
i) It requires a specialized heavy duty tablet press to form slug
ii) It does not permit uniform colour distribution as can be
iii) Achieved with wet granulation where the dye can be incorporated into binder liquid.
iv) The process tends to create more dust than wet granulation, increasing the potential contamination.


Steps in dry granulation
i) Milling of drugs and excipients
ii) Mixing of milled powders
iii) Compression into large, hard tablets to make slug
iv) Screening of slugs
v) Mixing with lubricant and disintegrating agent
vi) Tablet compression

Two main dry granulation processes

1.Slugging process
Granulation by slugging is the process of compressing dry powder of tablet formulation with tablet press having die cavity large enough in diameter to fill quickly. The accuracy or condition of slug is not too important. Only sufficient pressure to compact the powder into uniform slugs should be used. Once slugs are produced they are reduced to appropriate granule size for final compression by screening and milling.

Factors which determine how well a material may slug

i) Compressibility or cohesiveness of the mater
ii) Compression ratio of powder
iii) Density of the powder
iv) Machine type
v) Punch and die size
vi) Slug thickness
vii) Speed of compression
viii) Pressure used to produce slug


2.Roller compaction
The compaction of powder by means of pressure roll can also be accomplished by a machine called chilsonator. Unlike tablet machine, the chilsonator turns out a compacted mass in a steady continuous flow. The powder is fed down between the rollers from the hopper which contains a spiral auger to feed the powder into the compaction zone. Like slugs, the aggregates are screened or milled for production into granules.



Formulation for dry granulation
The excipients used for dry granulation are basically same as that of wet granulation or that of direct compression. With dry granulation it is often possible to compact the active ingredient with a minor addition of lubricant and disintegrating agent. Fillers that are used in dry granulation include the following examples: Lactose, dextrose, sucrose, MCC, calcium sulphate, Sta-Rx® etc.
Examples of some tablet formulation prepared by dry granulation


Advancement in Granulations


Steam Granulation

It is modification of wet granulation. Here steam is used as a binder instead of water. Its several benefits includes higher distribution uniformity, higher diffusion rate into powders, more favourable thermal balance during drying step, steam granules are more spherical, have large surface area hence increased dissolution rate of the drug from granules, processing time is shorter therefore more number of tablets are produced per batch, compared to the use of organic solvent water vapour is environmentally friendly, no health hazards to operators, no restriction by ICH on traces left in the granules, freshly distilled steam is sterile and therefore the total count can be kept under control, lowers dissolution rate so can be used for preparation of taste masked granules without modifying availability of the drug. But the limitation is that it is unsuitable for thermolabile drugs. Moreover special equipments are required and are unsuitable for binders that cannot be later activated by contact with water vapour.

Melt Granulation / Thermoplastic Granulation

Here granulation is achieved by the addition of meltable binder. That is binder is in solid state at room temperature but melts in the temperature range of 50 – 80˚C. Melted binder then acts like a binding liquid. There is no need of drying phase since dried granules are obtained by cooling it to room temperature. Moreover, amount of liquid binder can be controlled precisely and the production and equipment costs are reduced. It is useful for granulating water sensitive material and producing SR granulation or solid dispersion. But this method is not suitable for thermolabile substances. When water soluble binders are needed, Polyethylene Glycol (PEG) is used as melting binders. When water insoluble binders are needed, Stearic acid, cetyl or stearyl alcohol, various waxes and mono-, di-, & triglycerides are used as melting binders.

Moisture Activated Dry Granulation (MADG)

It involves moisture distribution and agglomeration. Tablets prepared using MADG method has better content uniformity. This method utilizes very little granulating fluid. It decreases drying time and produces granules with excellent flowability.

Moist Granulation Technique (MGT)

A small amount granulating fluid is added to activate dry binder and to facilitate agglomeration. Then a moisture absorbing material like Microcrystalline Cellulose (MCC) is added to absorb any excess moisture. By adding MCC in this way drying step is not necessary. It is applicable for developing a controlled release formulation.

Thermal Adhesion Granulation Process (TAGP)

It is applicable for preparing direct tableting formulations. TAGP is performed under low moisture content or low content of pharmaceutically acceptable solvent by subjecting a mixture containing excipients to heating at a temperature in the range from about 30ºC to about 130ºC in a closed system under mixing by tumble rotation until the formation of granules. This method utilizes less water or solvent than traditional wet granulation method. It provides granules with good flow properties and binding capacity to form tablets of low friability, adequate hardness and have a high uptake capacity for active substances whose tableting is poor.

Foam Granulation


Here liquid binders are added as aqueous foam. It has several benefits over spray(wet) granulation such as it requires less binder than Spray Granulation, requires less water to wet granulate, rate of addition of foam is greater than rate of addition of sprayed liquids, no detrimental effects on granulate, tablet, or invitro drug dissolution properties, no plugging problems since use of spray nozzles is eliminated, no overwetting, useful for granulating water sensitive formulations, reduces drying time, uniform distribution of binder throughout the powder bed, reduce manufacturing time, less binder required for Immediate Release (IR) and Controlled Release (CR) formulations

Sunday, 20 December 2015

SUN PHARMA 483 Observations for Halol Plant indicate serious GMP Issues.
•Compression Machines ( Point to Data Integrity Issue∗ )
•∗Compression machines are PLC controlled and can store data of events and alarm conditions which
occur during production. However the company does not document, review or evaluate alarm conditions or
events.
•Tablets are visually inspected for quality defects but there are no physical examples to visually
represent tablet defects.
•∗One of the qualifications of tableting process uses ‘X” number of tablet challenge articles.
However the company could not demonstrate that “x” number of challenge articles were used as challenge
articles were not available.
•Operation of compression machine requires performance checks to be conducted during the complete
process with action and alert limits for rejection. If the rejection is out of limits an investigation is
required to be performed. The rejected tablets are not evaluated for cause of rejection and unknown
contaminant. There is no data to support and provide scientific rationale for alert and action limits.